SCHEDULE 4
PART I CONTROLLED DRUGS SUBJECT TO THE REQUIREMENTS OF REGULATIONS 22, 23, 26 AND 27
1
The following substances and products, namely—
Alprazolam
Aminorex
Bromazepam
Brotizolam
Camazepam
Chlordiazepoxide
F51–(3–chlorophenyl)piperazine
F51–(3–chlorophenyl)–4–(3–chloropropyl)piperazine
Clobazam
Clonazepam
Clorazepic acid
Clotiazepam
Cloxazolam
Delorazepam
Diazepam
Estazolam
Ethyl loflazepate
Fencamfamin
Fenproporex
Fludiazepam
Flurazepam
Halazepam
Haloxazolam
F21...
F22...
Ketazolam
Loprazolam
Lorazepam
Lormetazepam
Medazepam
Mefenorex
Mesocarb
F4...
Nimetazepam
Nitrazepam
Nordazepam
Oxazepam
Oxazolam
Pemoline
Pinazepam
Prazepam
Pyrovalerone
F24Remimazolam
Tetrazepam
Triazolam
N-Ethylamphetamine
F19Zaleplon
F1Zolpidem
F20Zopiclone
2
Any stereoisomeric form of a substance specified in paragraph 1.
3
Any salt of a substance specified in paragraph 1 or 2.
4
Any preparation or other product containing a substance or product specified in any of paragraphs 1 to 3, not being a preparation specified in Schedule 5.
F185
A liquid formulation—
a
containing a botanical extract of cannabis—
i
with a concentration of not more than 30 milligrams of cannabidiol per millilitre, and not more than 30 milligrams of delta-9-tetrahydrocannabinol per millilitre, and
ii
where the ratio of cannabidiol to delta-9-tetrahydrocannabinol is between 0.7 and 1.3,
b
which is dispensed through a metered dose pump as a mucosal mouth spray, and
c
which was approved for marketing by the Medicines and Healthcare Products Regulatory Agency on 16th June 2010
PART IIF17Controlled Drugs Excepted From the Prohibition on Possession; Excluded from the Application of Offences Arising from the Prohibition on Importation and Exportation when Carried Out in Person for Administration to That Person; and Subject to the Requirements of Regulations 22, 23, 26 and 27
1
The following substances, namely—
F65α–Androstane–3,17–diol
F6Androst-4-ene-3,17-diol
F61–Androstenediol
F61–Androstenedione
F24-Androstene-3, 17-dione
F75–Androstenedione
F25-Androstene-3, 17 diol
Atamestane
Bolandiol
Bolasterone
Bolazine
Boldenone
F10Boldione
Bolenol
Bolmantalate
Calusterone
4-Chloromethandienone
Clostebol
F8Danazol
F8Desoxymethyltestosterone
F23Dienedione (estra-4, 9-diene-3,17-dione)
Drostanolone
Enestebol
Epitiostanol
Ethyloestrenol
Fluoxymesterone
Formebolone
Furazabol
F9Gestrinone
F93–Hydroxy–5α–androstan–17–one
Mebolazine
Mepitiostane
Mesabolone
Mestanolone
Mesterolone
Methandienone
Methandriol
Methenolone
Methyltestosterone
Metribolone
Mibolerone
Nandrolone
F1119–Norandrostenedione
F319-Nor-4-Androstene-3, 17-dione
F319-Nor-5-Androstene-3, 17 diol
F1219–Norandrosterone
Norboletone
Norclostebol
Norethandrolone
F1319–Noretiocholanolone
Ovandrotone
Oxabolone
Oxandrolone
Oxymesterone
Oxymetholone
Prasterone
Propetandrol
F14Prostanozol
Quinbolone
Roxibolone
Silandrone
Stanolone
Stanozolol
Stenbolone
Testosterone
F15Tetrahydrogestrinone
Thiomesterone
Trenbolone
2
Any compound (not being Trilostane or a compound for the time being specified in paragraph 1 of this Part of this Schedule) structurally derived from 17-hydroxyandrostan-3-one or from 17-hydroxyestran-3-one by modification in any of the following ways, that is to say -
a
by further substitution at position 17 by a methyl or ethyl group;
b
by substitution to any extent at one or more of positions 1, 2, 4, 6, 7, 9, 11 or 16, but at no other position;
c
by unsaturation in the carbocyclic ring system to any extent, provided that there are no more than two ethylenic bonds in any one carbocyclic ring;
d
by fusion of ring A with a heterocyclic system.
3
Any substance which is an ester or ether (or, where more than one hydroxyl function is available, both an ester and an ether) of a substance specified in paragraph 1 or described in paragraph 2 of this Part of this Schedule.
4
5
Any stereoisomeric form of a substance specified or described in any of paragraphs 1 to 4 of this Part of this Schedule.
6
Any salt of a substance specified or described in any of paragraphs 1 to 5 of this Part of this Schedule.
7
Any preparation or other product containing a substance or product specified or described in any of paragraphs 1 to 6 of this Part of this Schedule, not being a preparation specified in Schedule 5.
Sch. 4 Pt. 2 heading substituted (23.4.2012) by The Misuse of Drugs (Amendment No.2) (England, Wales and Scotland) Regulations 2012 (S.I. 2012/973), regs. 1(1), 15